



HAL
open science

Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study

Cédric Rat, Charlotte Grimault, Gaelle Quereux, Maelenn Dagherne, Aurélie Gaultier, Amir Khammari, Brigitte Dreno, Jean Michel Nguyen

► To cite this version:

Cédric Rat, Charlotte Grimault, Gaelle Quereux, Maelenn Dagherne, Aurélie Gaultier, et al.. Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. *BMJ Open*, 2015, 5 (7), pp.e007471. 10.1136/bmjopen-2014-007471 . inserm-01820036

HAL Id: inserm-01820036

<https://inserm.hal.science/inserm-01820036>

Submitted on 21 Jun 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

BMJ Open Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study

Cédric Rat,^{1,2} Charlotte Grimault,¹ Gaelle Quereux,^{2,3} Maelenn Dagorne,¹ Aurélie Gaultier,⁴ Amir Khammari,^{2,3} Brigitte Dreno,^{2,3} Jean-Michel Nguyen^{2,4}

To cite: Rat C, Grimault C, Quereux G, *et al.* Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. *BMJ Open* 2015;**5**: e007471. doi:10.1136/bmjopen-2014-007471

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2014-007471>).

Received 16 December 2014
Revised 26 April 2015
Accepted 28 April 2015



CrossMark

¹Department of General Practice, Faculty of Medicine, Nantes, France

²French National Institute of Health and Medical Research (INSERM U892)/National Centre for Scientific Research (CNRS U6299)—Team 2, Nantes, France

³Oncodermatology Department, Nantes University Hospital, Nantes, France

⁴Department of Epidemiology and Biostatistics, Nantes University Hospital, Nantes, France

Correspondence to

Dr Cédric Rat;
cedric.rat@univ-nantes.fr

ABSTRACT

Objective: To evaluate the efficacy of a targeted screening for melanoma in high-risk patients following the receipt of a mailed invitation to an annual skin examination by a general practitioner (GP).

Methods: A prospective cohort study was conducted in a primary care setting in western France. A total of 3897 patients at elevated risk of melanoma (identified using the Self-Assessment of Melanoma Risk Score) consented to participate in a targeted melanoma screening project in 2011. One year later, the participants were invited by mail to consult their GP for an annual skin examination. Efficacy of the procedure was evaluated according to patient participation and the number of melanomas detected. The consultation dates and results were collected during the 12 months postreminder and were analysed using SAS. Analyses of whether participation decreased compared with that during the year of inclusion and whether populations at risk for thick melanoma showed reduced participation in the screening were performed.

Results: Of the 3745 patients who received the mailed invitation, 61% underwent a skin examination. The participation of patients at risk for thick melanoma (any patient over 60 years of age and men over 50 years of age) was significantly greater than that of the patients in the other subgroups (72.4% vs 49.6%, $p<0.001$; and 66% vs 52.4%, $p<0.001$, respectively). The patients referred to the dermatologist after 1 year were more compliant compared with those referred during the first year (68.8% vs 59.1%, $p=0.003$). Six melanomas were detected within 1 year postreminder; therefore, the incidence of melanoma in the study population was 160/100 000.

Conclusions: This study confirms the benefits of developing a targeted screening strategy in primary care. In particular, after the annual reminder, patient participation and the diagnosis of melanoma remained high in the patients at elevated risk of thick melanomas.

Trial registration number: NCT01610531.

INTRODUCTION

In France, the incidence of melanoma is estimated at 10.8/100 000 for men and

Strengths and limitations of this study

- The study was conducted in a primary care setting.
- The participants were patients at elevated risk of melanoma who were recruited using a validated and reproducible procedure based on the Self-Assessment of Melanoma Risk Score.
- Six months after receiving an annual reminder to consult their general practitioner for a targeted screening for melanoma, 61% of the patients underwent a skin examination.
- The participation of patients at risk for thick melanoma was significantly above average.
- Six melanomas were detected. These results yielded a crude melanoma incidence of 160/100 000 in the cohort population and 469/100 000 in the men older than 50.

11/100 000 for women.¹ Overall, the incidence increased by 3.5 between 1980 and 2012.¹ Since the lesions are visible, they should be detected at an early stage through skin examination. However, in 2012, melanoma was responsible for 1672 deaths in France.¹ The main prognostic factor is the Breslow thickness (in millimetres) at the time of diagnosis.² The 5-year survival rate of patients with localised melanoma is 98.1%, compared with only 16.1% for patients with metastatic melanoma.³ Despite these findings, routine screening by full skin examination is not recommended in France,⁴ the USA,⁵ Australia or New Zealand, although the latter has the highest incidence of this disease worldwide.^{6 7} Indeed, the efficacy of routine screening in decreasing the mortality rate for these patients has not been proven,⁵ and routine screening would be expensive to perform.⁸

Conducting targeted screenings based on the identification of high-risk participants

could be a more valuable⁹ and cost-effective strategy.^{8 10 11} The following main risk factors for melanoma are well known:^{12–14} a personal or family history of melanoma, the presence of greater than 40 naevus, the presence of atypical naevus, skin phenotype I or II, freckles and actinic damage and a history of sunburns. Certain demographic groups have also been identified as being at higher risk of *thick* melanoma,^{9 15} including men, individuals over 60 years of age^{16 17} and men over 50 years of age.¹⁸ However, there is a need to define the best way to identify, screen and follow individuals at high risk of primary cutaneous melanoma.¹⁹

A low physician density has also been associated with the identification of thick melanomas.^{20–22} Melanomas tend to be thinner when they are detected by physicians rather than patients and also when they are detected during screening skin examination rather than during routine care.^{17 23–27} However, only 20% of patients who

have had melanoma report that they previously consulted a dermatologist.²⁸ Therefore, general practitioners (GPs) could play a significant role in the screening of these patients. One study has reported that the proportion of melanomas diagnosed by GPs in France increased from 24% in 2004 to 42% in 2008 following the implementation of a system requiring patients to register their attending physician.²⁹

On the basis of these findings, our team has developed a targeted melanoma screening procedure grounded in primary care, using the Self-Assessment of Melanoma Risk Score (SAMScore). This score is based on a 7-item self-administered questionnaire (figure 1) that a patient can answer without specific medical knowledge (30–32) and allows for the selection of a population at high risk of melanoma during primary care consultations.^{30–33} The SAMScore algorithm allows for the expression of risk in a dichotomous format (either

Figure 1 Questionnaire used for the Self-Assessment of Melanoma Risk Score.

Answer each question by circling the corresponding option:

1. What phenotype of skin do you have?
 - . Skin phenotype I: very fair skin, blond or red hair, light eyes (blue or green), never tan and always sunburn after sun exposure
 - . Skin phenotype II: fair skin, blond or light-brown hair, light eyes (blue or green), usually sunburn
 - . Skin phenotype III: deep skin, brown hair, light to medium eye colour
 - . Skin phenotype IV: olive skin, dark-brown hair, brown eyes
 - . Skin phenotype V: brown skin, black hair, black eyes
 - . Skin phenotype VI: black skin, black hair, black eyes
2. Do you have freckles? Yes / No
3. Approximately how many moles do you have on both arms? More than 20 / Fewer than 20
4. Have you had one or more episodes of a severe blistering sunburn during your childhood or teenage years? Yes / No
5. Have you lived in a country where the level of sunshine is high (Africa, French West Indies, the southern United States, Australia, etc.) for more than one year? Yes / No
6. Have you been diagnosed with melanoma (a skin cancer arising in melanocytes, the skin cells that make skin pigment) in the past? Yes / No
7. Have any of your first-degree relatives (parents, children, brother or sister) ever had melanoma? Yes / No / Don't know

According to the SAMScore, a patient is considered at elevated risk for melanoma if at least one of the following 3 criteria is met:

- . First criterion: The presence of at least 3 risk factors among the following 7 risk factors: skin phenotype I or II, a freckling tendency, >20 melanocytic nevi on both arms, experienced severe sunburn during their childhood or teenage years, residing in a country at low latitude, a history of previous melanoma, and a history of melanoma in a first-degree relative.
- . Second criterion: Under 60 years of age and >20 melanocytic nevi on both arms.
- . Third criterion: Sixty years of age or older and a freckling tendency.

at elevated risk or not for melanoma; figure 1). According to the SAMScore, a patient is considered at elevated risk for melanoma if at least one of the following three criteria is met: (1) the presence of at least three risk factors among the following seven risk factors: phenotype I or II, a freckling tendency, >20 melanocytic naevus on both arms, experienced severe sunburn during the childhood or teenage years, resides in a country at low latitude, a history of previous melanoma and a history of melanoma in a first-degree relative; (2) under 60 years of age and >20 melanocytic naevus on both arms; and (3) 60 years of age or older with a freckling tendency. Previous research based on a literature review has suggested a relative risk of 13.77 in the selected high-risk population.^{31 32} The SAMScore has been used to create a cohort of patients at high risk of melanoma (COPARIME) who were then asked to participate in a pilot targeted screening for melanoma (NCT01610531).³³ The targeted melanoma screening procedure comprised the following three steps: (1) identifying high-risk patients using the SAMScore; (2) asking GPs to perform a total skin examination on these high-risk patients; and (3) referring patients to a dermatologist if needed (for patients requiring a specialist opinion according to the GP). Between April and October 2011, 3917 patients were included, nine of whom had melanoma. The crude incidence observed during the first year of screening (229/100 000) highlighted the potential benefit of such a targeted screening.³³

However, the generalisability of the findings based on a 1-year intervention might be low. A major issue is the compliance of high-risk patients selected by the SAMScore who would be asked to consult yearly for melanoma screening and to consult a dermatologist in the case of a suspicious lesion.³⁴ Specific attention should be paid to patients at high risk of *thick* melanoma (including men, individuals over 60 years of age and men over 50 years of age) because their concern for melanoma screening has been reported to be lower compared with other high-risk patients.^{16–18}

Our team contacted all patients at risk of melanoma from the COPARIME cohort at 1 year after their inclusion in the targeted screening procedure. They received a mailed invitation to reconsult their GP for an annual skin examination. The aim of the study was to evaluate the efficacy of the mailed reminder, based on the following two variables: patient participation (with a specific focus on populations at risk of thick melanoma) and the number of melanomas detected.

METHODS

Design of the study

This study was based on a prospective follow-up of the COPARIME cohort. The patients were initially enrolled between 11 April and 30 October 2011, by 78 GP volunteers in western France, specifically in the departments of Loire-Atlantique and Vendée. All dermatologists in both

departments participated in the study. The dermatologist density is 5.3/100 000 inhabitants in Loire-Atlantique, a predominantly urban department, and 2.1/100 000 inhabitants in Vendée, a more rural department. These physician densities are comparable to those of other French departments (national mean: 5.3/100 000).³⁵

Participants

The eligibility criteria to receive the reminder at 1 year were as follows: being at high risk for melanoma according to the SAMScore, having agreed to participate in the targeted melanoma screening 1 year earlier, being over 18, and having no personal history of melanoma. Twenty patients were excluded from the COPARIME database, including 9 who had developed melanoma during the year since initially participating and had been directly recommended for a dermatologist follow-up and 11 who had died. As a result, a total of 3897 patients were eligible (figure 2).

Annual skin examination by a GP

An invitation to reconsult their GP for an annual skin examination was sent to eligible patients by mail at 1 year after their inclusion in the cohort.

The GP was asked to perform a total skin examination. Patients were referred to a dermatologist based on the opinion of the GP (as in routine care). The dermatologists were asked to classify their examinations of these referred patients according to the following three categories: 'benign lesion', 'lesion to monitor' and 'indication for exeresis'. When exeresis was indicated, the last step was anatomopathological examination.

Data collection

In addition to sending a reminder to the patients, each GP was mailed a table summarising the following data to be collected for each patient: the date of skin examination, the identification or not of a suspicious lesion and whether the patient was referred to a dermatologist. An updated table was sent to the GPs at months 6 and 12. If data were missing at 1 year after sending the reminder, an investigator contacted the GP by telephone and offered to visit the medical practice to facilitate data collection.

One year after the reminder was mailed to the last patient in the cohort, each dermatologist was mailed a table summarising the data to be collected for each patient, including the date of the dermatological consultation and the conclusion derived from the skin examination, that is, 'benign lesion', 'lesion to monitor' or 'indication for exeresis'. The anatomopathological result was also recorded when available. If data were missing, an investigator contacted the dermatologist by telephone and offered to visit the medical practice.

Between June and December 2013, all patients for whom no data were available were recontacted to determine whether they had consulted a dermatologist. All of the data collected during these telephone calls with




Figure 2 Participation among patients at elevated risk of melanoma at 6 months after a mailed reminder for an annual general practitioner skin examination.

patients were then confirmed or invalidated based on data from a physician (GP or dermatologist).

All of the data were recorded in an Access database.

Efficacy: patient participation and number of melanomas detected

Participation in the follow-up annual skin examination by the GP was assessed at 6 months after mailing the invitation.

Patient participation following the mailing of the invitation was analysed after the classification of the patients into the following six categories: (1) underwent the skin examination by the GP as expected; (2) directly consulted a dermatologist without reconsulting the GP, even though he/she had not consulted a dermatologist when his/her GP had referred him/her the previous year; (3) directly reconsulted his/her dermatologist as part of his/her dermatological follow-up; (4) directly reconsulted his/her dermatologist on his/her own initiative; (5) had no skin examination by his/her GP and no dermatological consultation; and (6) was referred to a dermatologist following examination by his/her GP but did not consult the dermatologist.

Melanoma cases were described using pathological reports.

Statistical analysis

Quantitative data are presented as the mean and median. Subgroup analysis was performed for the men, patients over 60 years of age, men over 50 years of age, and patients living in rural areas. Data from the first year were compared with data from the second year using the χ^2 and Fisher's exact tests. The GP effect was tested using Fisher's variance ratio test. Statistical significance was set at 0.05. R 3.10.0 software was used.

Opinion of the ethics committee

The ethics committee of Tours University Hospital has given a favourable opinion on the performance of the study (n°2011-R2-BRD 10/11-N).

RESULTS

Patient demographics

Of the 3897 patients, 117 moved without leaving a forwarding address, and 35 discontinued their participation




Figure 3 Participation in skin examinations by general practitioners and dermatologists among patients at elevated risk of melanoma based on a 2-year follow-up.

in the study, leaving 3745 patients for integration into the analysis. The mean age of the patients was 44.5 (± 15.6) years, and there were 1197 (32%) men. In total, 713 (19%) patients were over 60 years of age and 426 (11.3%) were men over 50 years of age. Finally, 2427 (64.8%) patients lived in Loire-Atlantique, 1206 (32.2%) in Vendée and 112 (3.25%) in other departments.

Patient participation

After the 1-year follow-up, 61% of the patients included in the targeted screening procedure reconsulted their GP, and 16% reconsulted a dermatologist (figure 3). A total of 17.1% of the cohort patients were lost to follow-up.

Figure 2 shows the six methods of patient participation, analysed at 6 months after the invitation was mailed to reconsult. A total of 264 (7%) patients directly

consulted a dermatologist, 2021 (54%) reconsulted their GP, and 1159 (31%) had no skin monitoring.

The proportion of referred patients who actually consulted a dermatologist increased after the reminder at 1 year compared with that on initial inclusion in the screening (68.8% vs 59.1%, $p < 0.001$). However, the overall proportion of cohort patients who consulted a dermatologist was lower (15.8% vs 23.9%, $p < 0.001$) because the proportion of patients referred to a dermatologist by the GPs was lower (12.2% vs 38.3%, $p < 0.001$; table 1). The GP effect, tested as a random factor for the corresponding variables, was not significant ($p = 0.10$ and $p = 0.32$, respectively).

Melanoma cases

A total of 83 patients underwent exeresis, and 6 melanomas, 5 squamous cell carcinomas and 15 basal cell

Table 1 Patient participation in a pilot melanoma targeted screening after an annual mailed reminder

	Year after annual reminder mailing		Year of inclusion		p Value
	Per cent	(n/N)	Per cent	(n/N)	
Proportion of included patients who attended the GP consultation	54.0	(2021/3745)	100.0	(3917/3917)	<0.001
Proportion of patients referred to a dermatologist	12.2	(247/2021)	38.3	(1502/3917)	<0.001
Proportion of referred patients who actually consulted the dermatologist	68.8	(170/247)	59.1	(887/1502)	0.003
Proportion of patients lost to follow-up	17.1	(665/3897)	2.6	(102/3917)	<0.001
Proportion of overall patients who had a dermatological skin examination	15.8	(616/3897)	23.9	(938/3917)	<0.001

GP, general practitioner.

Table 2 Characteristics of melanomas diagnosed during the 2-year follow-up of the COPARIME cohort

	N°	Gender	Patient age at diagnosis	Healthcare pathway	Type	Localisation	Breslow index (mm)	Delay between GP consultation and excision (days)
1st year of COPARIME targeted screening	1	F	31	Compliant	SSM	Forearm	0.16	24
	2	F	73	Compliant	Dubreuilh	Face	0	49
	3	M	64	Compliant	SSM	Back	0.8	49
	4	M	40	Compliant	SSM	Forearm	0.49	54
	5	M	51	Compliant	SSM	Back	0.245	106
	6	M	75	Compliant	Dubreuilh	Forearm	0.18	108
	7	F	34	Compliant	SSM	Thigh	0.52	124
	8				SSM	Thigh	0.15	124
	9	F	55	Patient's own initiative	SSM	Forearm	0	154
	10	M	56	Patient's own initiative	SSM	Back	0	286
2nd year of COPARIME targeted screening	11	F	71	Compliant	SSM	Thigh	0.45	33
	12	M	66	Compliant	Dubreuilh	Face	0	137
	13	M	59	Compliant	SSM	Bottom	0.38	191
	14	F	68	Referred in 2011, consulted after 2012 reminder	SSM	Calf	1.11	512
	15	M	42	Patient's own initiative	SSM	Back	0.43	513
	16	F	32	Referred in 2011, consulted after 2012 reminder	SSM	Back	0.242	709

	Breslow index (mm)			Delay between GP consultation and excision (days)		
	1st year	2nd year	p Value	1st year	2nd year	p Value
Mean	0.25	0.43	0.33*	107.8	349	0.077*
Median	0.17	0.405	0.65†	107	351	0.15†

*Student's t test.

†Fisher test.

F, female; GP, general practitioner; M, Male; SSM, superficial spreading melanoma.

carcinomas were diagnosed. The characteristics of the six melanomas are provided in table 2. Of the six melanomas, five were identified among the patients initially referred by their GP. The incidence of melanoma standardised to the populations of both departments was $183.7/10^5$ for men and $98.7/10^5$ for women.

The median thickness of the melanomas detected during the second year was 0.405 mm (table 2). One melanoma was greater than 1 mm thick, which was identified in a patient who had not consulted a dermatologist after having been referred the first year.

In men over 50 years of age, the exeresis rate (21% vs 11.6%, $p=0.029$) and the number of malignant lesions identified after exeresis (66.7% vs 21.5%, $p<0.001$) were higher compared with the reference group (table 3). In patients over 60 years of age, the number of malignant lesions identified after exeresis (66.7% vs 19.4%, $p<0.001$) was higher compared with the reference group (table 3).

DISCUSSION

Main results

Six months after receiving the annual reminder to schedule a total skin examination with their GP, 61% of the patients underwent a skin examination. Of them, 7.1% directly consulted a dermatologist. Of the patients who consulted their GP, 12.2% were referred to a specialist. The participation of populations at risk for thick melanoma was significantly above average. Six new melanomas were detected, corresponding to a crude incidence of 160/100 000.

Strengths and weaknesses

The strengths of this study are the size of the study population, the screening procedure initiated under primary care and under real care conditions, the use of a single validated and reproducible tool to detect

Table 3 Malignant lesions and participation in populations at elevated risk of advanced melanoma

	Men older than 50 % (n/N)	Others % (n/N)	>60 years old % (n/N)	<60 years old % (n/N)	p Value
Proportion of included patients who attended the GP consultation	66.0 (281/426)	52.4 (1740/3319)	72.4 (516/713)	49.6 (1505/3032)	<0.001
Proportion of patients referred to a dermatologist	11.4 (32/281)	12.4 (215/1740)	10.7 (55/516)	12.8 (192/1505)	0.24
Proportion of referred patients who actually consulted the dermatologist	87.5 (27/32)	66.5 (143/215)	70.9 (39/55)	68.2 (131/192)	0.83
Proportion of patients lost to follow-up	10.0 (43/430)	18.0 (522/2900)	8.0 (62/775)	19.0 (603/3174)	<0.001
Proportion of overall patients who had a dermatological skin examination	19.0 (81/426)	16.1 (535/3319)	17.7 (126/713)	16.2 (490/3032)	0.36
Proportion of exeresis decision after dermatologist consultation	21.0 (17/81)	11.6 (62/535)	15.9 (20/126)	12.0 (59/490)	0.32
Proportion of malignant lesions among excised lesions	66.7 (12/18)	21.5 (14/65)	66.7 (14/21)	19.4 (12/62)	<0.001
Crude incidence of melanoma	469/10 ⁵	120/10 ⁵	420/10 ⁵	99/10 ⁵	0.09

high-risk participants, and the prospective follow-up of the cohort.

This study also has certain limitations, including the number of patients lost to follow-up, the inclusion bias (women and young participants were over-represented in the population) and the absence of data on the false-negative rate of the procedure. Female over-representation is usually found in skin screening programmes^{36–39} and more generally in cancer screening.^{40–41} This bias could also be related to the population seeking consultation in general practice, which is not entirely representative of the general population.^{33–42}

Last but not least, this study was conducted in a French setting and involved GPs who were volunteers; thus, the generalisability of the findings should be considered with caution. The study design was grounded in a healthcare system in which GPs have a mission of regulating access to secondary care. This organisation has been implemented in a large majority of European countries.⁴³ However, national specificities may affect the referral and management procedures. Other variations may also appear in relation to discrepancies in the use of dermoscopy.

Interpretation of the results and comparison with data from the literature

The 61% rate of participation in the annual skin examination is higher than the rates observed for other cancers in France, including 52.1% for mammography,⁴⁴ 34.3% for Hemocult II⁴⁵ and 58.7% for cervical smear.⁴⁶ This good participation rate, observed after the 1-year reminder, is a significant result that indicates the success of the screening. Offering a targeted screening rather than a screening of the general population could be associated with better participation.

Six melanomas with a median Breslow thickness of 0.405 mm were diagnosed during the second year of follow-up, and only one melanoma was greater than 1 mm thick. Similarly, other authors have reported that screening procedures help to identify predominantly thin lesions with a median Breslow thickness of approximately 0.3 mm.^{32–47–48} The standardised incidence of melanoma in the high-risk population in this study was much higher than that which has been established in this geographic area (7.9 and 3.7 times higher for men and women, respectively). This increased incidence confirms that identifying patients at elevated risk of melanoma is relevant. This result is novel because most studies have only reported the benefit of a screening procedure immediately after the intervention. The observation of transient over-detection in these studies did not allow for an assessment of the benefit that would have been obtained if the screening procedure had been extended.^{32–33–49}

The present study confirms the potential benefit of GP consultation. First, five of the six new melanoma cases were identified among patients referred by their GP. Second, the concentration effect related to GP

consultation was increased. Indeed, the proportion of patients referred to a dermatologist by their GP decreased during the second year compared with the first year (12.2% vs 38.3%). This proportion is more consistent with previously published data that have revealed proportions of referred patients ranging from 7.4% to 26%.^{36 50–52} This evolution could be explained by the need for GPs to perform an initial dermatologist reference examination during the year of inclusion, whereas their role would subsequently be to ensure the absence of evolution of pre-existing lesions.

The benefit of the proposed screening seemed the highest in the populations at risk of thick melanoma. Men, participants over 60 years of age, and men over 50 years of age accounted for 32%, 19% and 11.3% of the cohort population, respectively, but they accounted for 50%, 50% and 33% of the melanoma patients, which is consistent with the findings of other authors.^{18 51 53} No very thick melanomas (>3 mm) were detected in our high-risk population over the course of 2 years. We were not able to conclude whether this result was due to the efficacy of the screening procedure or if it was simply related to the low incidence of thick melanomas in the population. The only melanoma greater than 1 mm was paradoxically detected during the second year: the corresponding patient had been referred to a dermatologist during the first year, but he did not consult the dermatologist until more than 1 year later. For this type of minimally compliant patient, our mailed reminder could have communicated to the patient that he or she was responsible for any appointment made. Thus, the benefits of a primary care-based targeted screening on the incidence of very thick melanomas could be due not only to the involvement of GPs trained in screening,⁵² but also to the impact of a simple annual reminder on minimally compliant patients.

Finally, 95 patients consulted a dermatologist on their own initiative, one of whom had a melanoma. This finding is consistent with the results of other studies showing that certain individuals participating in skin screening programmes appropriately pursue consultations on their own.^{36 49 54–57} In our study, it is likely that patients who were sensitised to their risk status and educated in skin self-examination by their GP directly consulted a dermatologist when they identified a suspicious lesion.

Practical implications and perspectives

In our study, we evaluated a generic procedure that addresses the reported limits of numerous national guidelines.¹⁹ The identification of high-risk individuals was based on a validated tool. We assessed a reproducible procedure for the clinical management of individuals defined as high risk, involving the mailing of a yearly invitation for a clinical skin examination performed by a GP.

More than half of the patients identified as being at risk for melanoma according to the SAMScore responded positively to our mailed reminder about

scheduling an annual skin examination with their GP. The high melanoma incidence and low melanoma thickness identified in this study are both in favour of a targeted screening conducted in primary care.

Extending the follow-up of our cohort would allow for an assessment of the proportion of false negatives related to GP examinations. Other major issues that should be addressed include assessments of the follow-up pace to be proposed in this population and the related costs. The validation of a beneficial effect of this screening procedure on mortality will require a randomised study.

Acknowledgements The authors wish to thank the French National Institute of Cancer for its financial support and the GPs for their participation in the COPARIME targeted melanoma screening project.

Contributors CR conceived the study, participated in its design and supervision and was responsible for the GP network and for drafting the manuscript. CG participated in the design of the study, was responsible for the data collection and helped to draft the manuscript. GQ participated in the design of the study, managed the pathological reports and helped to draft the manuscript. MD participated in the data collection and helped to draft the manuscript. AG performed the statistical analysis and helped to draft the manuscript. AK and BD participated in the design, of the study were responsible for the dermatologist network and provided administrative and technical support. J-MN participated in the design of the study, was responsible for statistical analysis and study supervision, and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding This study was funded and supported by the French National Institute of Cancer (€206 000) (<http://www.e-cancer.fr>).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The ethics committee of the University Hospital of Tours approved this study (n° 2011-R2-BRD 10/11-N).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Binder-Foucard F, Belot A, Delafosse P, *et al*. *Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1—Tumeurs solides*. Saint-Maurice, France: Institut de Veille Sanitaire, 2013.
2. Balch CM, Gershenwald JE, Soong S-J, *et al*. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol Off J Am Soc Clin Oncol* 2009;27:6199–206.
3. How Many People Survive 5 Years Or More after Being Diagnosed with Melanoma of the Skin? <http://seer.cancer.gov/statfacts/html/melan.html#survival> (accessed 10 Sep 2014).
4. Haute Autorité de Santé. Stratégie de diagnostic précoce du mélanome. 2006. <http://www.has-sante.fr/>
5. U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2009;150:188–93.
6. Cancer Council Australia, New Zealand, Ministry of Health, *et al*. Clinical practice guidelines for the management of melanoma in Australia and New Zealand: evidence-based best practice guidelines. Sydney, NSW, New Zealand: Cancer Council Australia; Australia Cancer Network; Ministry of Health, 2008.

7. Bray F, Ren J-S, Masuyer E, *et al*. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. *Int J Cancer* 2013;132:1133–45.
8. Losina E, Walensky RP, Geller A, *et al*. Visual screening for malignant melanoma: a cost-effectiveness analysis. *Arch Dermatol* 2007;143:21–8.
9. Curiel-Lewandrowski C, Chen SC, Swetter SM, *et al*. Screening and prevention measures for melanoma: is there a survival advantage? *Curr Oncol Rep* 2012;14:458–67.
10. Freedberg KA, Geller AC, Miller DR, *et al*. Screening for malignant melanoma: a cost-effectiveness analysis. *J Am Acad Dermatol* 1999;41:738–45.
11. Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. *Eur J Cancer Prev* 2015;24:141–9.
12. Gandini S, Sera F, Cattaruzza MS, *et al*. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. *Eur J Cancer Oxf Engl* 1990 2005;41:28–44.
13. Gandini S, Sera F, Cattaruzza MS, *et al*. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. *Eur J Cancer Oxf Engl* 1990 2005;41:45–60.
14. Gandini S, Sera F, Cattaruzza MS, *et al*. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. *Eur J Cancer Oxf Engl* 2005;41:2040–59.
15. Geller AC, Swetter SM, Oliveria S, *et al*. Reducing mortality in individuals at high risk for advanced melanoma through education and screening. *J Am Acad Dermatol* 2011;65:S87–94.
16. Geller AC, Elwood M, Swetter SM, *et al*. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. *Cancer* 2009;115:1318–27.
17. Swetter SM, Pollitt RA, Johnson TM, *et al*. Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. *Cancer* 2012;118:3725–34.
18. Geller AC, Sober AJ, Zhang Z, *et al*. Strategies for improving melanoma education and screening for men age \geq 50 years: findings from the American Academy of Dermatological National Skin Cancer Screening Program. *Cancer* 2002;95:1554–61.
19. Watts CG, Dieng M, Morton RL, *et al*. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. *Br J Dermatol* 2015;172:33–47.
20. Van Durme DJ, Ullman R, Campbell RJ, *et al*. Effects of physician supply on melanoma incidence and mortality in Florida. *South Med J* 2003;96:656–60.
21. Stitzenberg KB, Thomas NE, Dalton K, *et al*. Distance to diagnosing provider as a measure of access for patients with melanoma. *Arch Dermatol* 2007;143:991–8.
22. Aneja S, Aneja S, Bordeaux JS. Association of increased dermatologist density with lower melanoma mortality. *Arch Dermatol* 2012;148:174–8.
23. Helfand M, Mahon SM, Eden KB, *et al*. Screening for skin cancer. *Am J Prev Med* 2001;20:47–58.
24. Epstein DS, Lange JR, Gruber SB, *et al*. Is physician detection associated with thinner melanomas? *J Am Med Assoc* 1999;281:640–3.
25. McPherson M, Elwood M, English DR, *et al*. Presentation and detection of invasive melanoma in a high-risk population. *J Am Acad Dermatol* 2006;54:783–92.
26. Aitken JF, Elwood M, Baade PD, *et al*. Clinical whole-body skin examination reduces the incidence of thick melanomas. *Int J Cancer* 2010;126:450–8.
27. Richard MA, Grob JJ, Avril MF, *et al*. Delays in diagnosis and melanoma prognosis (II): the role of doctors. *Int J Cancer* 2000;89:280–5.
28. Geller AC, Koh HK, Miller DR, *et al*. Use of health services before the diagnosis of melanoma: implications for early detection and screening. *J Gen Intern Med* 1992;7:154–7.
29. Grange F, Barbe C, Mas L, *et al*. The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France. *Br J Dermatol* 2012;167:1351–9.
30. Quéréux G, Nguyen J-M, Volteau C, *et al*. Creation and test of a questionnaire for self-assessment of melanoma risk factors. *Eur J Cancer Prev* 2010;19:48–54.
31. Quéréux G, Moyse D, Lequeux Y, *et al*. Development of an individual score for melanoma risk. *Eur J Cancer Prev* 2011;20:217–24.
32. Quéréux G, Nguyen J-M, Cary M, *et al*. Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. *Eur J Cancer Prev* 2012;21:588–95.
33. Rat C, Quéréux G, Grimault C, *et al*. Melanoma incidence and patient compliance in a targeted melanoma screening intervention. One-year follow-up in a large French cohort of high-risk patients. *Eur J Gen Pract* 2014;1:1–7.
34. Rat C, Quéréux G, Monegier du Sorbier M, *et al*. Patients at elevated risk of melanoma: individual predictors of non-compliance to GP referral for a dermatologist consultation. *Prev Med* 2014;64:48–53.
35. Démographie médicale interactive/Démographie médicale. Cons. Natl. Médecins. <http://demographie.medicin.fr/demographie> (accessed 13 Sep 2014).
36. Breitbart EW, Waldmann A, Nolte S, *et al*. Systematic skin cancer screening in Northern Germany. *J Am Acad Dermatol* 2012;66:201–11.
37. Androlonis R, Secrest AM, McGuire ST, *et al*. The influence of age and sex on reasons for seeking and expected benefits of skin cancer screening. *Arch Dermatol* 2010;146:1097–102.
38. De Rooij MJ, Rampen FH, Schouten LJ, *et al*. Factors influencing participation among melanoma screening attenders. *Acta Derm Venereol* 1997;77:467–70.
39. Argenziano G, Zalaudek I, Hofmann-Wellenhof R, *et al*. Total body skin examination for skin cancer screening in patients with focused symptoms. *J Am Acad Dermatol* 2012;66:212–19.
40. Davis JL, Buchanan KL, Katz RV, *et al*. Gender differences in cancer screening beliefs, behaviors, and willingness to participate: implications for health promotion. *Am J Mens Health* 2012;6:211–17.
41. Sach TH, Whynes DK. Men and women: beliefs about cancer and about screening. *BMC Public Health* 2009;9:431.
42. Green LA, Fryer GE, Yawn BP, *et al*. The ecology of medical care revisited. *N Engl J Med* 2001;344:2021–5.
43. Masseria C, Irwin R, Thomson S, *et al*. *Primary care in Europe*. European Commission report. 2009.
44. Institut National de Veille Sanitaire (InVS). Evolution des taux de participation au programme national de dépistage organisé du cancer du sein par classe d'âge, depuis 2005. <http://www.invs.sante.fr/fr/Dossiers-thematiques/Maladies-chroniques-et-traumatismes/Cancers/Evaluation-des-programmes-de-depistage-des-cancers/Evaluation-du-programme-de-depistage-du-cancer-du-sein/Indicateurs-d-evaluation/Evolution-des-taux-de-participation-au-programme-national-de-depistage-organise-du-cancer-du-sein-par-classe-d-age-depuis-2005> (accessed 22 Sep 2014).
45. Leuraud K, Jezewski-Serra D, Viguier J, *et al*. Colorectal cancer screening by guaiac faecal occult blood test in France: evaluation of the programme two years after launching. *Cancer Epidemiol* 2013;37:959–67.
46. Dupont N. *Données épidémiologiques sur le cancer du col de l'utérus—Etat des connaissances—Actualisation 2008*. Institut de Veille Sanitaire, 2008. http://opac.invs.sante.fr/doc_num.php?explnum_id=3243
47. Koh HK, Norton LA, Geller AC, *et al*. Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program. *J Am Acad Dermatol* 1996;34:971–8.
48. Carli P, De Giorgi V, Giannotti B, *et al*. Skin cancer day in Italy: method of referral to open access clinics and tumor prevalence in the examined population. *Eur J Dermatol* 2003;13:76–9.
49. Stratigos A, Nikolaou V, Kedicoglou S, *et al*. Melanoma/skin cancer screening in a Mediterranean country: results of the Euromelanoma Screening Day Campaign in Greece. *J Eur Acad Dermatol Venereol* 2007;21:56–62.
50. Veronesi A, Pizzichetta MA, De Giacomi C, *et al*. A two-year regional program for the early detection of cutaneous melanoma. *Tumori* 2003;89:1–5.
51. Aitken JF, Janda M, Elwood M, *et al*. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. *J Am Acad Dermatol* 2006;54:105–14.
52. Engelberg D, Gallagher RP, Rivers JK. Follow-up and evaluation of skin cancer screening in British Columbia. *J Am Acad Dermatol* 1999;41:37–42.
53. Waldmann A, Nolte S, Geller AC, *et al*. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations. *Arch Dermatol* 2012;148:903–10.
54. Mc Gee R, Elwood M, Williams S, *et al*. Who comes to skin checks? *N Z Med J* 1994;107:58–60.
55. Koh HK, Geller AC, Miller DR, *et al*. Who is being screened for melanoma/skin cancer? Characteristics of persons screened in Massachusetts. *J Am Acad Dermatol* 1991;24:271–7.
56. Paoli J, Danielsson M, Wennberg AM. Results of the 'Euromelanoma Day' screening campaign in Sweden 2008. *J Eur Acad Dermatol Venereol* 2009;23:1304–10.
57. Rat C, Quéréux G, Riviere C, *et al*. Targeted melanoma prevention intervention: a cluster randomized controlled trial. *Ann Fam Med* 2014;12:21–8.